News & Updates

Show Multimedia Only

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

26 Sep 2025

The addition of eldecalcitol therapy to risedronate results in increased lumbar spine (LS) bone mineral density (BMD) in osteopenic to osteoporotic postmenopausal women with breast cancer who are receiving an aromatase inhibitor (AI), according to a study.

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

26 Sep 2025

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

26 Sep 2025 by

The use of oral methylcobalamin is effective in lessening the severity of hand-foot syndrome, without any serious safety concerns, among women with HER2 negative early breast cancer who are treated with adjuvant capecitabine, a study has shown.

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

26 Sep 2025

Nicotinamide delivers for skin cancer prevention

25 Sep 2025 by

Treatment with the over-the-counter vitamin B3 derivative nicotinamide can lower the risk of new skin cancers, and this risk reduction is greater for cutaneous squamous cell carcinoma and when treatment is initiated after the first skin cancer, according to a large retrospective study.

Nicotinamide delivers for skin cancer prevention

25 Sep 2025

Personalized risk messages improve CRC screening uptake

24 Sep 2025

A recent study has shown that the inclusion of personalized risk for advanced colorectal neoplasia (ACN) in a decision aid or provider notification provides no overall effect, but it has led to an increase in the uptake of stool testing in one health system.

Personalized risk messages improve CRC screening uptake

24 Sep 2025

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

24 Sep 2025 by

At an industry-sponsored symposium during the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025 in Hong Kong, regional experts reflected on pioneering oncology drug development. Dr Jii Bum Lee of Yonsei Cancer Center, Seoul, Republic of Korea, discussed the unique translational and clinical journey of amivantamab, an EGFR-MET bispecific antibody, which was first established as a treatment for non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertion (exon20ins) mutations. Dr Herbert Loong of the Chinese University of Hong Kong shared the experience of advancing NBTXR3, a novel hafnium oxide–based nanoparticle radiosensitizer, into the clinic, underscoring the necessity of multidisciplinary collaboration for success.

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

24 Sep 2025

Original New Drug Application Approvals by US FDA (16-31 August 2025)

24 Sep 2025

New drug applications approved by US FDA as of 16-31 August 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 August 2025)

24 Sep 2025

Advances in ROS1-positive NSCLC treatment landscape

23 Sep 2025 by

ROS1 rearrangement is an actionable mutation present in 2–3 percent of Chinese patients with advanced non-small-cell lung cancer (NSCLC). At an industry-sponsored meeting chaired by Dr Herbert Loong of the Department of Clinical Oncology at the Chinese University of Hong Kong (CUHK), experts discussed challenges in ROS1-positive NSCLC management, presented clinical data and shared real-world experience of using repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), in TKI-naïve and -experienced patients.

Advances in ROS1-positive NSCLC treatment landscape

23 Sep 2025

Achieving deep PSA response and early management of skin rash in a mHSPC patient treated with ADT plus ARPI

23 Sep 2025 by

A 72-year-old retired male construction worker, who was an ex-smoker and social drinker and had good past health, presented with lower urinary tract symptoms and back pain in December 2023. Subsequent testing revealed an elevated prostate-specific antigen (PSA) level of 19 ng/mL. A 12- core transrectal prostate biopsy carried out on 9 January 2024 showed tumour infiltration of >90 percent across all cores, with a Gleason score of 5+4, and perineural invasion.

Achieving deep PSA response and early management of skin rash in a mHSPC patient treated with ADT plus ARPI

23 Sep 2025

Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?

23 Sep 2025 by

A landmark analysis of data from a Hong Kong prostate cancer database found that use of proton-pump inhibitors (PPIs) was associated with inferior oncological outcomes in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who received upfront docetaxel.

Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?

23 Sep 2025

Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?

23 Sep 2025 by

Research findings from Yonsei Cancer Center in South Korea, presented at European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025, suggest a correlation between butyrate-producing Faecalibacterium enrichment and clinical response to pembrolizumab with or without chemotherapy in treatment-naïve patients with metastatic non-small-cell lung cancer (mNSCLC).

Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?

23 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

Nicotinamide delivers for skin cancer prevention

Nicotinamide delivers for skin cancer prevention

Personalized risk messages improve CRC screening uptake

Personalized risk messages improve CRC screening uptake

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

Original New Drug Application Approvals by US FDA (16-31 August 2025)

Original New Drug Application Approvals by US FDA (16-31 August 2025)

Advances in ROS1-positive NSCLC treatment landscape

Advances in ROS1-positive NSCLC treatment landscape

Achieving deep PSA response and early management of skin rash in a mHSPC patient treated with ADT plus ARPI

Achieving deep PSA response and early management of skin rash in a mHSPC patient treated with ADT plus ARPI

Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?

Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?

Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?

Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?